Borge, Laurence

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma

Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences

Cancer, Lipids, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 454

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 421

Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions

Olivares, O., Mayers, J. R., Gouirand, V., Torrence, M. E., Gicquel, T., Borge, L., Lac, S., Roques, J., Lavaut, M.-N., Berthezène, P., et al. (2017) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 413

Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer

Masoud, R., Reyes-Castellanos, G., Lac, S., Garcia, J., Dou, S., Shintu, L., Abdel Hadi, N., Gicquel, T., El Kaoutari, A., Diémé, B., et al. (2020) · Cell Reports Medicine

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 175